Papillary Thyroid Cancer - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Papillary Thyroid Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Papillary Thyroid Cancer - Pipeline Review, H2 2014', provides an overview of the Papillary Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Papillary Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Papillary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Papillary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Papillary Thyroid Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Papillary Thyroid Cancer - Overview 7
Pipeline Products for Papillary Thyroid Cancer - Comparative Analysis 8
Papillary Thyroid Cancer - Therapeutics under Development by Companies 9
Papillary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 10
Papillary Thyroid Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Papillary Thyroid Cancer - Products under Development by Companies 14
Papillary Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
GlaxoSmithKline plc 17
Plexxikon Inc. 18
Novartis AG 19
Exelixis, Inc. 20
Deciphera Pharmaceuticals, LLC 21
Papillary Thyroid Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 31
vandetanib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
everolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cabozantinib s-malate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
dabrafenib mesylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rebastinib tosylate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PLX-7486 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CLM-3 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CLM-29 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Papillary Thyroid Cancer - Recent Pipeline Updates 52
Papillary Thyroid Cancer - Dormant Projects 70
Papillary Thyroid Cancer - Discontinued Products 71
Papillary Thyroid Cancer - Product Development Milestones 72
Featured News & Press Releases 72
May 06, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains European Orphan Drug Status 72
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 72
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products under Development for Papillary Thyroid Cancer, H2 2014 7
Number of Products under Development for Papillary Thyroid Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Papillary Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014 16
Papillary Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 17
Papillary Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2014 18
Papillary Thyroid Cancer - Pipeline by Novartis AG, H2 2014 19
Papillary Thyroid Cancer - Pipeline by Exelixis, Inc., H2 2014 20
Papillary Thyroid Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 30
Papillary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014 52
Papillary Thyroid Cancer - Dormant Projects, H2 2014 70
Papillary Thyroid Cancer - Discontinued Products, H2 2014 71